Avanos Medical (AVNS)
(Delayed Data from NYSE)
$23.71 USD
-0.43 (-1.78%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $23.72 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.71 USD
-0.43 (-1.78%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $23.72 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum C VGM
Zacks News
Centene's Michigan Unit Partners With Mae to Reduce Health Disparities
by Zacks Equity Research
CNC's Meridian unit collaborates with Mae to improve health outcomes and address health disparities in Michigan.
Molina Healthcare Stock Rises 15.4% in 3 Months: Should You Buy?
by Zacks Equity Research
MOH stock is expected to benefit from contract wins, rising premiums and expansion initiatives.
Are Investors Undervaluing Avanos Medical (AVNS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smart Investors Are Holding Acadia Healthcare Stock Now: Here's Why
by Zacks Equity Research
ACHC is expected to benefit from improved volumes, patient day growth and expansion initiatives.
Why Avanos Medical (AVNS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Avanos Medical Stock May Gain From Brand Partnership With NFL
by Zacks Equity Research
AVNS' GAME READY announces a paid partnership with NFL defensive end and San Francisco 49ers star, Nick Bosa.
Centene's Unit Secures New Four-Year Medicaid Contract in Iowa
by Zacks Equity Research
CNC's unit, Iowa Total Care, wins a new contract to provide Medicaid managed care services, enhancing its presence in Iowa and bringing improved health outcomes in the state.
Acadia Healthcare Expands Behavioral Health Services in Iowa
by Zacks Equity Research
ACHC breaks ground on a new behavioral health hospital in Council Bluffs, addressing regional care shortages through a joint venture with Methodist Health System.
Is Avanos Medical (AVNS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Implied Volatility Surging for Avanos (AVNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Avanos (AVNS) stock based on the movements in the options market lately.
Align Technology (ALGN) Encounters Low ASP, FX Headwinds
by Zacks Equity Research
Align Technology's (ALGN) Clear Aligner ASP is facing a significant impact of unfavorable foreign exchange across multiple currencies.
Should Value Investors Buy Avanos Medical (AVNS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
Phibro's (PAHC) Animal Health business, supported by the flourishing Vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts
by Zacks Equity Research
Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.
Avanos Medical (AVNS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 17.24% and 0.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
Globus Medical (GMED) Up 7.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Integra (IART) Up 26% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
Avanos Medical (AVNS) Q1 Earnings Beat Estimates (Revised)
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of +4.76% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Q1 Earnings Lag Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -9.52% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
Why Is Integra (IART) Down 4% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.
New Strong Sell Stocks for January 16th
by Zacks Equity Research
AMFPF, ADI and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 16, 2024.